February 24 | 2022
2cureX publishes interim report for the fourth quarter and all 12 months of 2021
Read more
February 23 | 2022
2cureX holds a virtual live-session on the 25th of February 2022 to present and discuss the Interim report for the fourth quarter of 2021.
Read more
February 23 | 2022
2cureX reorganizes to an even stronger distributor focus
Read more
January 21 | 2022
New Institutional shareholder
Read more
January 11 | 2022
IndiTreat® to be distributed in Czech Republic and Slovakia through Promedica
Read more
January 5 | 2022
IndiTreat® to be distributed in Poland by Perlan Technologies
Read more
December 22 | 2021
First IndiTreat® order received from Labormed, Slovenia
Read more
December 16 | 2021
First hospital joins the IndiTreat® Evaluation Program IGNITE
Read more
December 14 | 2021
2cureX launches IndiTreat® mCRC Start test to guide 1st line treatment
Read more
December 13 | 2021
2cureX reaches the goals for the 2021 rollout plan
Read more
December 9 | 2021
2cureX signs yet another distribution agreement – this time with Omnigen Medical Products in Turkey
Read more
November 29 | 2021
EU publishes an article about the successful finalization of 2cureX’s MicroCaT project.
Read more
November 25 | 2021
2cureX offentliggör delårsrapport för det tredje kvartalet och första nio månader 2021
Read more
November 25 | 2021
2cureX publishes interim report for the third quarter and first nine months of 2021
Read more
November 24 | 2021
2cureX expands its Clinical Advisory Board with Professor Andrew Beggs, Queen Elizabeth Hospital Birmingham, UK
Read more
November 23 | 2021
2cureX holds a virtual live-session on the 26th of November 2021 to present and discuss the Interim report for the third quarter of 2021.
Read more
October 29 | 2021
Mangold Fondkommission AB published an updated Analyst Report on 2cureX
Read more
October 29 | 2021
2cureX – Banbrytande cancerbehandlingstest rullas ut – Mangold Insight Analys
Read more